Podcasts about Colorectal cancer

What's it like when you are the only African American dancer in a world of all white dancers? Lisa continues our very special interview with Jennifer Jones, the first African American Rockette. Jennifer talks about growing up seeing Broadway shows with her parents. She told her high school guidance counselor that she wanted to go to college and major in dance. Her counselor told her that she wasn't ready for college yet, although at a very early age, she always dreamed of being on stage. She was so passionate and started at a local community college before moving to New York City, auditioning, and getting hired to be a Rockette. She talks about how spectacular Radio City Music Hall is. It literally took her breath away! She shares the excitement of the famous Christmas Spectacular show and how she poured her heart into each show. She was performing up to six shows a day. Jennifer discusses resilience, and what she had to break through to make her dreams come true. She noted that this year is the 100-year anniversary of the Rockettes and a big event will be planned to celebrate. She also talks about her challenges, and how important it is to believe in yourself. She discusses the importance of being resilient. When she turned 50, she went to her doctor to request a colonoscopy. The doctor told her she was young and had nothing to worry about as she was healthy and had no family members with colorectal cancer. Jennifer listened to her powerful intuition and got a colonoscopy anyway. The doctors determined that she had colorectal cancer, and she was told she had five years to live. She felt embarrassed by this diagnosis as she was always the “healthy one” in her family. She was physically fit and a vegetarian. She met with a specialist and had four rounds of chemotherapy. To the amazement of her doctors, the tests showed dramatic improvement. She explains how she decided to meditate more, let go of toxic relationships, drink green juices, and so much more. She knew she needed to change the way she ate and the way she thought. In 2019, she was deemed cancer-free! Jennifer talks about testing early for colorectal cancer, and especially in the African American community. If there's a history in your family, it's important to test even earlier. She shares how her symptoms started as pressure in her abdomen, so she began changing her diet and meeting with doctors. She talks about organizations who can offer early detection and additional support including Colorectal Cancer Alliance: https://colorectalcancer.org and Colon Cancer Foundation: https://coloncancerfoundation.org. Jennifer's groundbreaking memoir is titled “Becoming Spectacular: The Rhythm of Resilience from the First African American Rockette.” This is Part 2 of the interview. Info: rockettejenn.com.

Dr. Shaalan Beg and Dr. Kristen Ciombor discuss practice-changing studies in GI cancers and other novel treatment approaches that were presented at the 2025 ASCO Annual Meeting. Transcript Dr. Shaalan Beg: Hello, I'm Dr. Shaalan Beg, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas, Texas. There were some remarkable advances in gastrointestinal cancers that were presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Kristen Ciombor to discuss some exciting GI data. Dr. Ciombor is the Ingram Associate Professor of Cancer Research and a co-leader of Translational Research and the Interventional Oncology Research Program at the Vanderbilt Ingram Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Ciombor, it's great to have you on the podcast today. Dr. Kristen Ciombor: Thanks, Dr Beg. It's great to be here. Dr. Shaalan Beg: Alright, let's kick it off. Big year for GI cancers. We'll start off with LBA1. This was the ATOMIC study sponsored by NCI and the National Clinical Trials Network (NCTN) and the Alliance group. This is a randomized study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III mismatch repair deficient colorectal cancer. Dr. Kristen Ciombor: I think this study was really definitely practice-changing, as you can tell because it was a Plenary. But I do have some concerns in terms of how we're actually going to implement this and whether this is the final answer in this disease subtype. So, as you said, the patients were enrolled with stage III resected mismatch repair deficient colon cancer, and then they were randomized to either modified FOLFOX6 with or without atezolizumab. And that's where it starts to become interesting because not many of us give FOLFOX for 6 months like was done in this study. Obviously, the study was done over many years, so that was part of that answer, but also the patients received atezolizumab for a total of 12 months. So the question, I think, that comes from this abstract is, is this practical and is this the final answer? I do think that this is practice-changing, and I will be talking to my patients with resected mismatch repair deficient colon cancer about FOLFOX plus atezolizumab. I think the big question is, do these patients need chemotherapy? And can we do a neoadjuvant approach instead? And that's where we don't have all the answers yet. Dr. Shaalan Beg: Yeah, but it has been great to see immunotherapy make its way into the adjuvant space after having made such a big impact in the metastatic space, but still some unanswered questions in terms of the need for chemotherapy and then the duration of therapy, which I guess we'll have to stay tuned in for the next couple of years to to get a lot of those questions answered. Dr. Kristen Ciombor: Yeah, but a big congratulations to the study team, to the NCTN, the NCI. I mean, this is really a great example of federally funded research that needs to continue. So, great job by the study team. The DFS 10% difference is really very large and certainly a practice-changing study. Dr. Shaalan Beg: Yeah, and and sticking with colon cancer, and and this another federally funded study, but this time funded by a Canadian cancer clinical trials group was LBA3510. This is the CHALLENGE study. It's a randomized phase 3 trial of the impact of a structured exercise program on disease-free survival for stage III or high-risk stage II colon cancer. This study got a lot of buzz, a lot of mainstream press coverage, and a lot of discussions on what that means for us for the patients who we're going to be seeing next week in our clinic. What was your takeaway? Dr. Kristen Ciombor: Yeah, this is a really interesting study, and I was so glad to see it presented because this partially answers one of the questions that patients always have for us in clinic, right? You know, once they've completed their standard chemotherapy and surgery, what else can they do to help prevent recurrence? And so we've always known and sort of extrapolated that healthy lifestyle habits are good, but now we have data, particularly in these patients. Most of them were stage III colon cancer patients, those had high-risk stage II cancer. And basically, the goal was to increase their physical activity by at least 10 MET hours per week. So, my big question, of course, as I came into this presentation was, “Okay, what does that mean exactly? How does that translate to real life?” And really what the author presented and explained was that basically most patients could hit their target by adding a 45- to 60-minute brisk walk 3 to 4 times a week. So I think this is very approachable.  Now, in the confines of the study, this was a structured exercise program, so it wasn't just patients doing this on their own. But I do think kind of extrapolating from that, that this is very achievable for most patients. And not only did this prevent recurrence of their prior cancer, but actually the rate of new primary cancer diagnoses, was less, which is really interesting, especially in the breast and prostate cancer. So this was a really interesting, and I think practice-changing study as well, especially given that this is something that most patients can do. Dr. Shaalan Beg: Yeah, and there was a lot of discussion in the hallways after the presentation in terms of how this really changes our existing practice because most folks already recommend exercise as a way for improving outcomes in cancer patients. So we've already been doing that. Now we have some data on how much it can impact the benefit. But there was some discussion about what the actual degree of impact was. There was a drop-off rate in terms of how long folks were able to stick with this exercise regimen. But you've seen this in clinic when someone have their surgery, they have their chemotherapy, they've been so intimately involved with the oncology world, with the oncology practice, and they somehow feel that they're being let loose into this mean, angry world without any guidance and they're looking for something to do. “What more can I do in terms of my lifestyle?” And then here we have very solid data, as solid as can be for an intervention like exercise, showing that there is an impact and you can give a prescription for exercise when someone wraps up their chemotherapy for colon cancer, thanks to the study. Dr. Kristen Ciombor: Yeah. It was a great study. Dr. Shaalan Beg: Moving to gastroesophageal cancer, another late-breaking abstract. This is LBA5. The MATTERHORN trial was a phase 3 trial of durvalumab plus FLOT for resectable GE junction and gastric cancer. And again, another area where immunotherapy has made an impact, and here we're seeing it move closer for earlier-stage disease. What was your take-home for the MATTERHORN trial? Dr. Kristen Ciombor: Yeah, so this study looked at neoadjuvant perioperative durvalumab plus our current standard chemotherapy of FLOT versus placebo plus FLOT. And this was a large study, almost 1,000 patients were randomized. And the primary endpoint was event-free survival, and it was definitely met in favor of the D + FLOT arm, as Dr. Klempner discussed after Dr Janjigian's presentation. I do think there are still some unanswered questions here. Overall survival is not yet mature, so we do have to wait and see how that shakes out. But it's very interesting and kind of is reflective of what, as you said, we're looking at earlier and earlier lines of therapy, particularly with immunotherapy, in these GI cancer spaces. So it makes a lot of sense to test this and and to look at this. So the toxicity was pretty similar to what we would expect. Primary endpoint was met, but again, we'll have to wait and see what the survival data looks like. Dr. Shaalan Beg: Yeah, and in oncology, we know, especially for treatment that does add additional cost, it does add additional potential toxicity that we want to see that overall survival nudged. I did see some polls on social media asking folks whether their practices changed from this, and I think the results were favoring adding durvalumab for this group of patients but understanding that there are caveats to the addition of treatments and the eventual FDA approval in that indication as well. Dr. Kristen Ciombor: Exactly. I completely agree with that. Dr. Shaalan Beg: All right. How about we stick with gastroesophageal cancer? LBA4002 was trastuzumab deruxtecan versus ramucirumab plus paclitaxel for second-line treatment in HER2-positive unresectable or metastatic gastric cancer or GE junction cancer. This was the DESTINY-Gastric04 study. And again, antibody-drug conjugates making a big impact across different diseases. And here we have more data in the HER2-positive gastric cancer space. Your thoughts on this study? Dr. Kristen Ciombor: Yeah, so this is a really important space in gastroesophageal cancer because the HER2 positivity rate is fairly high as compared to some of our other tumor types. So, I do think one of the important things was that patients did have biopsy confirmation of HER2 status, which was very important, and then they were randomized to either T-DXd versus the kind of second-line standard of ramucirumab-paclitaxel. So this was a great practical study and really answers a question that we had for a while in terms of does anti-HER2 therapy in the second-line really impact and improve survival. So we did see a statistically significant improvement favoring T-DXd. I do think it's always important to look at toxicity, though, too. And there was about almost 14% rate of interstitial lung disease, which of course is the most feared toxicity from some of these antibody-drug conjugates, especially T-DXd. So I do think it's important to keep that in mind, but this is definitely a great addition to the armamentarium for these HER2-positive patients. Dr. Shaalan Beg: And pancreas cancer was on the stage after a very long time with a positive clinical trial. This is Abstract 4006. These were preliminary results from a phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone for previously untreated metastatic pancreas cancer. This is a frontline clinical trial of gemcitabine/nab-paclitaxel plus/minus the study drug. There were other cohorts in this study as well, but they reported the results of their part 3B arm. And great to see some activity in the pancreas space. And your thoughts? Dr. Kristen Ciombor: Yeah, we definitely need better treatments in pancreas cancer. This was a very welcome presentation to see. The elraglusib is an inhibitor of GSK-3beta, and it's thought that that mediates drug resistance and EMT. And so this is, I think, a perfect setting to test this drug. So patients basically were randomized. Patients with metastatic pancreas cancer were randomized 2: 1 to gemcitabine/nab-paclitaxel plus or minus this elraglusib. So, what we saw was that overall survival was better with the addition of this new drug. And overall, not only the 1-year overall survival, but also median overall survival.  The thing that was interesting, though, was that we saw that the overall survival rates were 9.3 months with the combination versus 7.2 months with just gemcitabine/nab-paclitaxel. And that's a little bit lower than we've seen in other studies. So, not sure what was going on there. Was it the patients that were a bit sicker? Was it a patient selection, you know, thing? I'm not really sure how to explain that so much. Also, the toxicity profile was much higher in terms of visual impairment, with over 60% of patients being treated with the combination versus 9% with gemcitabine/nab-paclitaxel. So these were mild, grade 1 and 2, but still something to be cautious about. Dr. Shaalan Beg: And especially with this being a phase 2 trial, making sure that in a larger study we're able to better evaluate the toxicity and see if the control arm in the larger confirmatory study performs differently will be really important before this compound makes it to the clinic in our space. But very exciting to see these kinds of results for pancreas adenocarcinoma. Dr. Kristen Ciombor: Yeah. Dr. Shaalan Beg: We've talked, it seems, a couple of times on this podcast about the BREAKWATER clinical trial. We did hear PFS and updated OS data, updated overall survival data on first-line encorafenib plus cetuximab plus modified FOLFOX6 for BRAF-mutated colorectal cancer. This was LBA3500. And eagerly anticipated results – we have all previously heard the progression-free survival results – but here we heard updated overall survival results, and very well-received study it seemed from the audience that time. So what are your takeaways on the updated results for BREAKWATER? Dr. Kristen Ciombor: In my opinion, this was one of the most practice-confirming studies. As you mentioned, we've already seen some of the preliminary data of BREAKWATER at prior meetings. But really what was particularly impactful for me was the median overall survival with the BREAKWATER regimen. So, again, patients received FOLFOX, encorafenib cetuximab in the first line if they had BRAF-mutated V600E-mutated colorectal cancer. And the median PFS was 12.8 months, which was actually really remarkable in this traditionally very aggressive, poor prognosis subtype of tumors. So, by seeing a median overall survival of 30.3 months was just incredible, in my opinion. Just a few years ago, that was considered the median overall survival for all comers for metastatic colorectal cancer. And we know the median overall survival was more in the less than 12 months range for BRAF. So this was incredibly impactful, and I think should be absolutely practice-changing for anyone who is eligible for this regimen.  I think again, where the practice meets the study is what's kind of important to think about too, how long did patients get FOLFOX, and certainly it adds toxicity to add a BRAF-targeted regimen on top of FOLFOX already. So, one of the other interesting things about the study, though, was that even though it didn't complete treatment, they actually did look at encorafenib/cetuximab alone and in the first line without chemotherapy. And those preliminary results actually looked okay, especially for patients who might not be able to tolerate chemotherapy, which we certainly see in practice. So, overall, definitely more data. And I agree that it's certainly practice-changing. Dr. Shaalan Beg: And it completely, as you mentioned, changes the outlook for a person who's diagnosed with BRAF-mutated metastatic colon cancer today versus even 7 or 8 years ago. Dr. Kristen Ciombor: And we're seeing this over and over in other subtypes too, but how you choose to treat the patient up front really matters. So really giving the right regimen up front is the key here. Dr. Shaalan Beg: And along the same lines, Abstract 3501 wanted to answer the question on whether people with MSI-high metastatic colorectal cancer need double checkpoint inhibitor therapy or is single therapy enough. So this [CheckMate-8HW] study compared nivo plus ipi with nivo alone, nivo monotherapy for MSI-high metastatic colorectal cancer. And we've known that both of these are fairly active regimens, but we also know the chance of immune-related adverse events is significantly higher with combination therapy. So this was a much-needed study for this group of patients. And what were your takeaways here? Dr. Kristen Ciombor: This, of course, has been really nivo-ipi in the first-line MSI-high metastatic colorectal cancer is now a standard of care. And not everybody is eligible for it, and there could be reasons, toxicity reasons, and other things too. But as we've been seeing for the last couple of years, immunotherapy clearly beats chemo in this space. And now looking at doublet versus single immunotherapy treatment in the first line, I think really nivo-ipi does beat out monotherapy. I will say, however, there is a caveat in that we still haven't seen the nivo-ipi versus nivo in the first line. So what has been presented thus far has been across all lines of therapy, and that does muddy the waters a little bit. So definitely looking forward and and we've asked this many times and based on the statistical plan and and what not, you know, we just haven't seen that data yet. But I do think it's becoming increasingly important to consider doublet immunotherapy for these patients as long as there are no contraindications. With the again, with the caveat that we have to have these toxicity discussions in the clinic with patients because many patients can tolerate it, you know, this regimen fairly well, but there can be very severe toxicities. So, I think an informed discussion should really be had with each patient before moving forward. Dr. Shaalan Beg: Yeah, informed decision, making them aware of the potential of real significant toxicities, immune-related toxicities with double therapy. But I am curious in your practice, how often do you see people choosing doublet therapy as frontline? Dr. Kristen Ciombor: So patients are really savvy, and a lot of times they've heard this data before or have come across it in patient advocacy groups and other things, and it's really nice to be able to have that conversation of the risk versus benefit. So I will say not all of my patients choose doublet, and many of them are still cured with immunotherapy monotherapy. So the big question there is, will we ever understand who actually needs the doublet versus who can still be cured or have very good long-term outcomes with just the single agent? And that has not been answered yet. Dr. Shaalan Beg: What a great point. So the last abstract I was hoping we could talk about is POD1UM-303 or the INTERAACT2 subgroup analysis and impact of delayed retifanlimab treatment for patients with squamous cell carcinoma of the anal canal. What were your thoughts here? Dr. Kristen Ciombor: This was a study, actually we saw at ESMO, we saw the primary data at ESMO last year, and this was an update with some exploratory analyses. But this was really an important study because once again, we're looking at immunotherapy in later lines of therapy. That's how we started looking at and investigating immunotherapy, and now we're moving it up and up in the treatment course. So this was a study of carboplatin/paclitaxel plus or minus retifanlimab. Actually it was retifanlimab versus placebo. And it was a positive study, as we heard last year. This actually led to FDA approval of this regimen last month, just before ASCO, and it has now been incorporated in the NCCN guidelines as the preferred first-line option.  So what I thought was important from the additional data presented at ASCO was looking at the different subgroups, it did not appear that patients with liver mets or not had different outcomes. So that was really good to see because sometimes in colon cancer we see that immunotherapy doesn't work as well when patients have liver mets. And interestingly, because we use immunotherapy in anal cancer without any biomarkers, unlike with colon cancer or some of the other tumor types, also the authors looked at PD-L1 status, and it did look like maybe patients did a little bit better if they had higher PD-L1 expression, but patients still could benefit even if they were PD-L1 negative. So that was important, I think, and we will continue to see further data come out from this study. I want to mention also that EA2176 just completed accrual, so that was carbo-taxol plus or minus nivolumab. And so we should be seeing that data sometime soon, which will hopefully also confirm the ongoing role for immunotherapy in the first-line setting for anal cancer. Dr. Shaalan Beg: That was a fantastic review. Thank you, Dr Ciombor. Thanks for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Kristen Ciombor: Thanks for having me here. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Shaalan Beg  @ShaalanBeg  Dr. Kristen Ciombor @KristenCiombor Follow ASCO on social media:    @ASCO on Twitter   @ASCO on BlueSky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Shaalan Beg:   Consulting or Advisory Role: Ipsen, Cancer Commons, Foundation Medicine, Science37, Nant Health, Lindus Health Speakers' Bureau: Sirtex Research Funding (Inst.): Delfi Diagnostics, Universal Diagnostics, Freenome Dr. Kristen Ciombor: Consulting or Advisory Role: Pfizer, Incyte, Exelixis, Bayer, ALX Oncology, Tempus, Agenus, Taiho Oncology, Merck, BeiGene Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calthera, Genentech, Seagen, Syndax Travel, Accommodations, Expenses: Incyte, Tempus

BUFFALO, NY – June 24, 2025 – A new precision #oncology paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.” In this report, led by Alberto Hernando-Calvo from Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology; Razelle Kurzrock from WIN Consortium and Medical College of Wisconsin; Oncotarget Editor-in-Chief Wafik S. El-Deiry from WIN Consortium and Legorreta Cancer Center at Brown University; and corresponding author Shai Magidi, also from WIN Consortium, along with colleagues, describe the case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. After analysis, the WIN International Molecular Tumor Board proposed different personalized treatment plans based on the tumor's unique genetic mutations. This case highlights the growing role of precision oncology in guiding therapies for patients with treatment-resistant cancers. Colorectal cancer is one of the deadliest cancers worldwide, and managing advanced cases remains a significant challenge. This patient had already received five prior treatment regimens, including chemotherapy and targeted therapies. Although some treatments were initially beneficial, the cancer eventually developed resistance. Molecular analysis revealed key mutations in genes such as BRAF, MET, APC, TP53, and NRAS, which are often linked to aggressive tumor behavior and reduced treatment effectiveness. With limited standard options left, the patient's case was presented and reviewed by the WIN International Molecular Tumor Board, a global panel of cancer experts. The team analyzed the clinical history and genetic profile to design new treatment approaches. These involved off-label drug combinations tailored to the specific mutations found in the tumor. For example, one approach combined trametinib, a drug that blocks cancer cell growth signals, with amivantamab, an antibody that attacks cancer-related proteins MET and EGFR, and regorafenib, which helps cut off blood supply to tumors and may counteract effects from APC and TP53 mutations. “Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily.” This case reflects a shift in cancer care from standardized protocols to precision approaches, where therapy is selected based on a tumor's molecular features. Such strategies aim to delay resistance and slow disease progression more effectively. The WIN International Molecular Tumor Board also discussed practical challenges, including access to medications, combining off-label drugs, and the difficulties of enrolling patients in clinical trials after multiple prior treatments. Although the ultimate treatment decision remained with the patient's physician, this report shows how international collaboration and precision oncology can expand options for patients facing limited alternatives. It also emphasizes the value of repeat genetic analysis during disease progression to monitor new mutations in the tumor that may impact treatment. While the patient ultimately died from cancer progression, this case serves as a model for how molecular analysis and expert input can be used to guide treatment even in complex and metastatic colorectal cancer. As personalized cancer strategies continue to evolve, they may offer potential pathways for patients who have exhausted standard treatment options. DOI - https://doi.org/10.18632/oncotarget.28744 Correspondence to - Shai Magidi - shai.magidi@winconsortium.org Video short - https://www.youtube.com/watch?v=uWDtWNgpK7A To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

In this powerful and deeply personal conversation, Orly Fuerst opens up about her journey from Israel to Houston and her life-changing diagnosis of stage four colorectal cancer. With honesty, humor, and unwavering determination, Orly shares how she continues to run, parent, and teach while undergoing intensive treatment. She explores the critical role of resilience, self-trust, and finding balance in the face of overwhelming health challenges. Orly also highlights the importance of compassionate healthcare relationships and the strength she draws from her community. Her story is not just one of survival—it's a testament to living fully, with purpose and courage, even in the most uncertain moments.Orly Fuerst is a mother of six, a dedicated runner, and a passionate teacher. For years, her world revolved around raising her children and nurturing her students. But everything changed in July of 2022, when she was diagnosed with Stage 4 Colorectal Cancer that had already spread to her liver, lungs, and lymph nodes. Doctors told her she had just 6 to 9 months to live.Her immediate response captured her spirit: “Oh no, that won't work—I already paid for a race 10 months away.” In that moment, Orly became a cancer patient, but she refused to let the disease define her.She continues to undergo treatment, including chemotherapy and occasional radiation—always with grit, humor, and resilience. While some days are harder than others, Orly is determined not to let cancer become her entire identity. She remains deeply committed to spreading awareness about the power of movement and exercise, particularly in the frum community, where these conversations can sometimes be overlooked.Orly is currently training for a 10K in November to raise awareness for colon cancer, and a half marathon in January. Through her running, teaching, and advocacy, she continues to defy the odds—one step, one mile, one message at a time.Sponsor the JOWMA Podcast! Email admin@jowma.orgBecome a JOWMA Member! www.jowma.orgFollow us on Instagram! www.instagram.com/JOWMA_orgFollow us on Twitter! www.twitter.com/JOWMA_medFollow us on Facebook! https://www.facebook.com/JOWMAorgStay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

The rhetoric and violence are both escalating on all sides in the Iran-Israel war. U.S. President Donald Trump is now demanding Iran's unconditional surrender, while appearing to threaten the country's supreme leader. Iran and Israel are firing missiles at each other. And Israeli Prime Minister Benjamin Netanyahu hints at regime change – in Iran.Also: Mark Carney is trying to make the most of what's left of the G7 in Alberta. The leaders kept their meetings going without the most consequential member: Trump. The U.S. president left last night – one day ahead of schedule. Even without him, leaders are focused on delivering more help to Ukraine and putting more pressure on Russia.And: New warnings about colorectal cancer. More young people are being diagnosed with it – and advocacy groups are calling for screening at a younger age.Plus: Indigenous groups protest the One Canadian Economy bill, 23andme fails to protect privacy, and more.

Send us a textAshley and Danielle discuss the significant relationship between vitamin D levels and colorectal cancer risk, particularly in individuals with IBD. We talk about the role of Vitamin D in inflammation reduction, and the importance of maintaining optimal vitamin D levels for overall health. We highlight research findings that suggest higher vitamin D levels may correlate with lower rates of colon cancer!  We always emphasize with our patients that supplementation strategies are very individualized and based on the patient's health conditions and dietary intake. So, please check with your doctor or dietitian about your vitamin D levels and possible supplementation if needed. TakeawaysVitamin D is crucial for immune function and inflammation regulation.Many individuals with IBD are at risk for vitamin D deficiency.A research study shows that higher vitamin D levels may lead to lower colorectal cancer rates.Regular testing of vitamin D levels is important, especially for those with IBD.Diet alone may not provide sufficient vitamin D; supplementation is often necessary.Individual health status and lifestyle factors should guide vitamin D supplementation.Consulting healthcare providers about vitamin D levels is essential.Maintaining optimal vitamin D levels can decrease other health risks too.00:00- The Link Between Vitamin D and Colorectal Cancer03:11- Understanding Vitamin D's Role in Inflammatory Bowel Disease06:04- Optimal Vitamin D Levels and Recommendations09:10- Individualized Approaches to Vitamin D SupplementationFollow us on instagram @crohns_and_colitis_dietitiansFollow us on youtube @thecrohnscolitisdietitiansWe love helping provide quality content on IBD nutrition and making it more accessible to all through our podcast, instagram and youtube channel. Creating the resources we provide comes at a significant cost to us. We dream of a day where we can provide even more free education, guidance and support to those with IBD like us. We need your support to do this. You can help us by liking episodes, sharing them on your social media, subscribing to you tube and telling others about us (your doctors, friends, family, forums/reddit etc). Can you do this for us? In return, I promise to continually level up what we do here.

How food impacts the menopause | weight loss jabs | the battles around non dairy | supplements | cholesterol | the process of ultra processed food | ZOE's Daily 30

This week's topics include treating hot flashes in breast cancer survivors, a blood test for detecting colorectal cancer, exercise to improve survival after colorectal cancer treatment and CAR-T therapy for solid tumors.Program notes:0:40 CAR-Ts for solid tumors1:40 Advanced gastric or gastroesophageal cancer2:40 Cytokine release syndrome3:22 Exercise after treatment for colorectal cancer4:23 Disease free survival superior5:23 Currently not much exercise6:23 Potential mechanisms7:10 Treating hot flashes in breast cancer survivors8:10 Neurokinin receptors9:12 A blood test to screen for colorectal cancer10:12 Asymptomatic adults11:12 Will not replace FIT or screening colonoscopy12:12 Survival advantage due to polypectomy13:19 End

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from May 31-June 6, 2025.

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this episode, we look at three new pieces of research with implications for general practice.Firstly, can exercise prevent the recurrence of colorectal cancer? Short answer, yes. But how much exercise did you need to do, and what on earth is a MET? Secondly, what are the concerns around low-dose amitriptyline use for IBS from patients and GPs? How can we aid the discussion? Finally, can SLGT2 inhibitors improve liver disease? Is this the new treatment for our patients with MASLD (the condition formerly known as NAFLD? ReferencesNEJM Exercise and CRCMETs WikipediaBJGP IBS & amitriptyline prescribingBMJ SGLT2i & MASLDNB Blog MASLD: The rebrand you never heard ofwww.nbmedical.com/podcast

Colorectal cancer is the fourth most common cancer in the U.S. and the second leading cause of cancer death, but what if you could defeat it before it ever has a chance?About one in every 24 people will develop colorectal cancer in their lifetime. And most of the time, your genes are not to blame. So what can you do to lower your risk? First, eat a healthy diet that includes lots of fruits, veggies and whole grains.New research suggests you may also want to up your calcium intake. Researchers found adding 300 milligrams of calcium each day — which is about the amount in a glass of milk — was associated with a 17% lower risk for colorectal cancer.Get regular screenings. Most major organizations suggest you should start at age 45, but not everyone does. Colonoscopies not only look for cancer, they also can help doctors remove precancerous polyps, preventing future cancer.Stop smoking and don't drink in excess. Scientists reported that drinking an additional 20 grams of alcohol daily was linked to a 15% higher risk for colorectal cancer. That's about the amount in a large glass of wine.It's never too soon start.The number of people who have died from colorectal cancer has steadily decreased since the mid 1980s.Experts say this is due to more screening and changing lifestyles.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

June 2, 2025 ~ Dr. Sumit Singla MD, Director of Endoscopic Services Henry Ford Cancer Institute discusses why colorectal cancer is on the rise in young people.

Dr. Albert Bourla, CEO of Pfizer (PFE), joins Nicole Petallides on Morning Trade Live to discuss the latest results of his company's Braftovi drug trials. According to Dr. Bourla, results showed it can reduce risk of colorectal cancer deaths by 51%. He also offers an in-depth look into how Pfizer is advancing in other treatments and how its building capital to support them.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study. Join us as we delve into: •⁠  ⁠The significance of MSI-high status in colorectal cancer and its prevalence. •⁠  ⁠The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates. •⁠  ⁠The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy. •⁠  ⁠Important side effects associated with the combination therapy and how to manage them. •⁠  ⁠Insights on patient selection for immunotherapy, including considerations for age and comorbidities. •⁠  ⁠The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment. YouTube: https://youtu.be/wJRlECiY2VA Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025! #OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW

Colorectal cancer rates in adults over the age of 50 have been falling since the 1980s, but that's not the case for young adults. New research shows that colorectal cancer incidences and deaths are increasing in people under 50.If that trend continues, colorectal cancer is expected to become the leading cause of cancer-related deaths among young adults globally by 2030.Delaware Public Media's Kyle McKinnon sits down with Bayhealth colorectal surgeon Dr. Assar Rather to examine the rise in colorectal cancer for young people and how it's being addressed.

In this episode, Dr. Ruchika Talwar, a urologic oncologist at Vanderbilt University Medical Center, Dr. Adham Jurdi, a medical oncologist and Senior Director of Oncology at Natera, delve into the groundbreaking world of tumor-informed molecular residual disease testing. Discover how circulating tumor DNA (ctDNA) is revolutionizing cancer detection and treatment, providing real-time insights that surpass traditional imaging methods. Learn about the decades-long journey to perfect this technology, its clinical implications, and the exciting advancements on the horizon.

At 57, Ronnie was living a healthy, active life as a health coach, marathon runner, and triathlete. She had always taken great care of her health and never imagined that cancer would be part of her story—until June of 2018 after a routine colonoscopy, Ronnie was diagnosed with stage 4 colon cancer that had spread to liver, lungs, peritoneum and lymph nodes.   Faced with this grim prognosis, she chose to take an active role in her treatment. Ronnie opted for traditional chemotherapy but also incorporated naturopathic treatments into her regimen. Ronnie believed this combination would help support her body during the chemotherapy and aid in her healing. The journey wasn't easy, but the balance of conventional medicine and natural therapies helped her to stay strong and cope with the challenges she faced. Looking back, Ronnie realizes that her success wasn't just the result of traditional treatments or naturopathic therapies—it was her mindset, resilience, and refusal to give up. Cancer tried to take her life, but instead, it gave her a new one, one filled with gratitude, strength, and a deeper understanding of what truly matters. To learn more about Ronnie and her work visit, https://ronniecampbellauthor.com/ To purchase her book, Racing for a Miracle: A Stage 4 Survivor's Journey of Hope. Celebrating 5 Years Cancer-Free—A Story of Strength, Early Detection, and Miracles, visit https://ronniecampbellauthor.com/about-the-book/ Instagram @ronniecampbellauthor.com (https://www.instagram.com/ronniecampbell.author/) Facebook @ronnieswellness4life.com ( https://www.facebook.com/profile.php?id=100083650758740  )  Learn more about Colorectal Cancer Canada at https://www.colorectalcancercanada.com/ _________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube _____ Thank you to our friends from The Healing Oasis for sponsoring this episode of the podcast.  The Healing Oasis is a first of its kind in beautiful British Columbia, Canada where we encourage the body to heal from cancer using alternative therapies & cancer fighting meals at a wellness retreat center in nature. Our top naturopathic cancer doctor will prescribe a protocol tailored specifically for you. There's no place quite like it. Start your healing journey today! Learn More about The Healing Oasis by visiting these links: Website   Testimonials Video Overview

Can Gut Health in Childhood Help Prevent Bowel Cancer Later in Life?This week on the podcast, we're talking about something that might feel a little confronting but also incredibly empowering: how our kids' health today could shape their future health tomorrow.Bowel cancer rates are on the rise in young people, and new research is pointing to a surprising contributor — one we've been talking about for a long time here at Natural Super Kids: gut health. In this episode, we will break down what this means for parents without fear, but with practical action in mind.Here's what we cover:What the latest research says about childhood gut bacteria and bowel cancer risk.How early-life factors like C-section births, antibiotics, and diet can impact long-term gut health.Subtle signs that your child's gut may be out of balance — from tummy troubles to mood changes.Easy, gut-supportive changes you can start making right now (even if life feels busy).

Featuring perspectives from Dr Christopher Lieu and Dr Kanwal Raghav, including the following topics: Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Dr Lieu (0:00) Recent Advances in the Management of Metastatic CRC — Dr Raghav (32:58) CME information and select publications

Clinical investigators discuss available data guiding the management of colorectal cancer.  CME information and select publications here.

Clinical investigators discuss available data guiding the management of colorectal cancer.  CME information and select publications here.

Clinical investigators discuss available data guiding the management of colorectal cancer.  CME information and select publications here.

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Is minimally invasive ablation the future of metastatic cancer care? We now have the results of the COLLISION Trial, which investigates the non-inferiority of thermal ablation compared to surgical resection. How will these findings change treatment paradigms and practice patterns around metastatic colorectal cancer? In this week's episode of BackTable, interventional radiologist Dr. Chris Beck discusses the impact and implications of the COLLISION Trial with principal investigator Dr. Martijn Meijerink from Amsterdam UMC.---SYNPOSISThe doctors explore the COLLISION Trial's design, results, complication rates, and future directions. They also cover best practices for ablation techniques and the potential for interventional oncology to enter a “golden era.” Finally, Dr. Meijerink highlights the importance of standardizing intervention quality and being present in tumor boards to ensure optimal patient care.---TIMESTAMPS00:00 - Introduction 03:21 - Understanding Metastatic Colorectal Cancer and IR's Role05:18 - Introduction to the COLLISION Trial07:40 - Radiofrequency vs Microwave Ablation and Technological Advancements09:02 - Trial Design and Patient Eligibility16:20 - Ablation Techniques and Approaches22:05 - Trial Results and Analysis30:19 - Impact on Guidelines and Practice39:44 - Best Practices in Thermal Ablation43:27 - Future Directions in Interventional Oncology---RESOURCES“Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial.” (Meijerink, 2024)https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA3501

A recent #study from Assiut University Hospital in Egypt, published in #Oncotarget, presents a promising strategy for patients with metastatic #colorectalcancer (mCRC). The #research introduces a gentler yet effective maintenance therapy that may extend survival, enhance quality of life, and offer a more accessible treatment option for mCRC patients worldwide. The Challenge of Treating Metastatic Colorectal Cancer Colorectal cancer is one of the most common causes of cancer-related deaths worldwide. When it spreads to other parts of the body—a stage known as mCRC—it becomes much more difficult to treat. At this stage, clinicians often use strong drug combinations like FOLFOX or CAPOX, which mix chemotherapy drugs to stop cancer growth. FOLFOX combines three drugs given intravenously, while CAPOX includes two of the same drugs, with one taken as a pill. While effective, these treatments can cause serious side effects. For example, one of the main drugs, oxaliplatin, can lead to nerve damage, making it painful or difficult to use the hands and feet. Fatigue, diarrhea, and other issues are also common. Over time, these side effects may force clinicians to stop or adjust the treatment, even if it is working. That is where maintenance therapy comes in. After the cancer is controlled, clinicians often switch to a gentler treatment plan to keep it from returning. The challenge is finding a therapy that continues to work without causing too many side effects, especially in places where access to expensive or intensive treatments is limited. Full blog - https://www.oncotarget.org/2025/05/07/panitumumab-and-low-dose-capecitabine-a-promising-maintenance-therapy-for-metastatic-colorectal-cancer/ Paper DOI - https://doi.org/10.18632/oncotarget.28687 Correspondence to - Doaa A. Gamal - doaaalygamaal@gmail.com Video short - https://www.youtube.com/watch?v=wuPSS0EdK-8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28687 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Panitumumab, maintenance, colorectal cancer, Capecitabine About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode of The Patient From Hell, host Samira Daswani speaks with Dr. Sara Char about her journey into oncology, the evolution of cancer biology, and the significant role of the microbiome in colon cancer. They discuss the complexities of cancer survivorship, the effectiveness of different methods of delivering survivorship care plans, and the importance of colonoscopy in monitoring colorectal cancer. The conversation also delves into the impact of diet on cancer risk, emphasizing the need for a comprehensive understanding of dietary patterns rather than focusing solely on individual foods. In this conversation, Dr. Sara Char discusses various aspects of survivorship care for colorectal cancer patients, focusing on dietary recommendations, exercise, and the emotional challenges faced during the transition from active treatment to survivorship. The dialogue emphasizes the importance of balancing nutrition, understanding the role of GLP-1 agonists, and the need for a supportive care team. Additionally, the conversation highlights the unique mental health needs of survivors and the significance of providing patients with a roadmap for their cancer journey.About Our Guest:Dr. Sara Char is a hematology and oncology fellow at Dana-Farber Cancer Institute. She specializes in the care of patients with gastrointestinal cancers with a specific interest in young-onset colorectal cancer. Her research explores the molecular underpinnings of diet and lifestyle factors implicated in colorectal cancer development and progression. Dr. Char received her M.D. from Tufts University School of Medicine and completed her residency training in internal medicine at Massachusetts General Hospital, where she also served as chief resident. Outside of work, she is a self-identified foodie and devoted dog-mom. Resources & Links:This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features the PCORI research study here: https://pubmed.ncbi.nlm.nih.gov/34302474/ - ‘Simplifying Survivorship Care Planning: A Randomized Controlled Trial Comparing 3 Care Plan Delivery Approaches'Chapter Codes00:00 Exploring the Microbiome and Colon Cancer05:59 The Transition to Survivorship Care11:57 Understanding Adherence in Survivorship Plans17:49 The Role of Colonoscopy in Survivorship24:06 Dietary Patterns and Cancer Risk25:04 Inflammatory Diet and Health Outcomes28:11 Dietary Recommendations for Cancer Survivors30:34 Exercise and Body Composition in Cancer Care31:59 Managing GI Issues with GLP-1 Agonists34:43 Navigating Multidisciplinary Care35:50 The Transition from Active Treatment to Survivorship38:08 Mental Health Challenges Post-Treatment41:41 The Need for Psycho-Oncology Support46:47 The Importance of Patient Education and ResourcesConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.This episode was supported by an award from the Patient-Centered Outcomes Research Institute.

In this episode, Dr. Tejas Jayakrishnan discusses the rising incidence of young onset colorectal cancer (CRC) and the potential environmental factors contributing to this trend. The conversation delves into the importance of screening protocols, the challenges faced in early detection, and the role of education in increasing awareness and understanding of cancer risks. Dr. Jayakrishnan emphasizes the need for tailored approaches in patient care, particularly for younger patients, and highlights ongoing research efforts aimed at improving outcomes in this demographic.About Our Guest:Dr. Thejus Jayakrishnan is a gastrointestinal medical oncologist at Dana-Farber Cancer Institute and Brigham and Women's Hospital, and an Instructor in Medicine at Harvard Medical School. Originally from India, he completed his medical training in New Delhi and continued his journey through residency in Pittsburgh and oncology fellowship at Cleveland Clinic.Dr. Jayakrishnan's research explores why some people develop cancers like colorectal cancers at a younger age. He studies how metabolism, gut bacteria, and genetics contribute to these patterns, with the goal of developing better tools for screening and treatment.In the clinic, he treats patients with all types of gastrointestinal cancers and works closely with Dana-Farber's Young-Onset Colorectal Cancer Center. His focus is on translating scientific discoveries into meaningful improvements in care through clinical trials. Outside of work, he's an avid cyclist, outdoor enthusiast, and lover of books and movies.Resources & Links:This episode was supported by the Patient Centered Outcomes Research Institute (PCORI) and features the PCORI research study here: https://pubmed.ncbi.nlm.nih.gov/30578103/ - ‘Impact of including quantitative information in a decision aid for colorectal cancer screening: A randomized controlled trial'Chapter Codes:00:00 - Understanding Young Onset Colorectal Cancer10:03 - Screening Protocols and Challenges19:50 - The Role of Education in Cancer Awareness30:04 - Future Directions in Colorectal Cancer ResearchConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @MantaCares and visit our website at MantaCares.com for more episodes and updates.Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.This episode was supported by an award from the Patient-Centered Outcomes Research Institute. 

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-429 Overview: Colorectal cancer screening saves lives, yet many patients remain unscreened. This episode explores current screening methods, the evidence behind the new DNA blood test, and how it compares to existing options. Gain practical insights to guide patient discussions and improve screening rates in your practice. Episode resource links: N Engl J Med. 2024 Mar 14;390(11):973-983. doi: 10.1056/NEJMoa2304714 N Engl J Med 2024;390:984-93. DOI: 10.1056/NEJMoa2310336 Guest: Jillian Joseph, MPAS, PA-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-429 Overview: Colorectal cancer screening saves lives, yet many patients remain unscreened. This episode explores current screening methods, the evidence behind the new DNA blood test, and how it compares to existing options. Gain practical insights to guide patient discussions and improve screening rates in your practice. Episode resource links: N Engl J Med. 2024 Mar 14;390(11):973-983. doi: 10.1056/NEJMoa2304714 N Engl J Med 2024;390:984-93. DOI: 10.1056/NEJMoa2310336 Guest: Jillian Joseph, MPAS, PA-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed

Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed

Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed

CT colonography (CTC) is now at an inflection point following recent regulatory updates. In this AJR Conversation, Gastrointestinal Imaging Section Editor Federica Vernuccio, MD, PhD, speaks with David Kim, MD, about his team's recently published article on the use of CTC for colorectal cancer prevention and detection.

In this episode, host Jonathan Sackier speaks with Alexander Spira about cutting-edge advances in lung and colorectal cancer, including EGFR and KRAS-targeted therapies. They also discuss Spira's leadership in oncology research, his thoughts on the evolving ‘town-gown' dynamic in US medicine, and his hopes for the future of cancer care.  Timestamps:  00:00 – Introduction 01:50 – Most memorable family travel adventure 03:30 – What inspired you to go into oncology 05:49 – Three recent publications in lung cancer 07:02 – Real-world data on colorectal cancer 08:15 – Sex/gender differences in non-small cell lung cancer 11:53 – The science of KRAS mutations and drug development 15:07 – Accelerating diagnostics and access to therapies 17:13 – The ‘town-gown' debate in American healthcare 18:09- Three Wishes 

Morgan had not turned 45 yet, so she hadn't received a screening colonoscopy for colorectal cancer. But when she noticed blood in her stool at age 41, she did exactly what she should have and sought medical evaluation. After months of missteps became years of dismissive care, she realized it was time for a second opinion at Siteman Cancer Center. With the help of WashU Medicine radiation oncologist Hyun Kim, MD, co-director of the Young-Onset Colorectal Cancer Program, Morgan was given a treatment plan that provided the care she needed. In this episode, we discuss her persistence and dedication to getting herself the best care for her young-onset colorectal cancer diagnosis.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/cancer-types/colorectal/young-onset-colorectal-cancer-program/ https://siteman.wustl.edu/treatment/cancer-types/colorectal/prevention-and-screening/  https://siteman.wustl.edu/doctor/kim-hyun/ https://getscreenednow.com/colon-cancer/ https://getscreenednow.com/insurance/  

Ask your smart speaker to "Play One Oh Three One Austin"

For this special episode of the Astonishing Healthcare podcast, Andrew Barnell, CEO of Geneoscopy, joins Justin Venneri in the studio for an insightful discussion about colorectal cancer (CRC) screening in observance of National CRC Awareness Month! Andrew explains how he and his "very talented" sister, Erica Barnell, MD, PhD, co-founded Geneoscopy to develop diagnostic tests using RNA biomarkers extracted from stool samples. Their newly FDA-approved test, ColoSense™, provides a non-invasive alternative to traditional colonoscopies.Barnell highlights the rising incidence of CRC in younger adults, which prompted guideline changes to lower the recommended screening age to 45. He stresses the urgent need for increased screening awareness and greater access to screening tools, noting that employers can help overcome barriers to screening through education and by encouraging engagement in wellness programs. Other topics covered include:Over 135,000 people are diagnosed with CRC every year, and despite CRC being one of the most preventable cancers with good long-term survival rates following treatment, 50,000 people die from it annually. Preventive screenings are increasingly covered with no patient out-of-pocket costs, but insurers' expenses are rising.Increasing early screening is crucial: 30-40% of eligible individuals remain unscreened, particularly in the 45-49 age group.Geneoscopy's decentralized clinical trial and overall use of technology to conduct its pivotal FDA approval study virtually, which increased patient diversity and efficiency.Regulatory challenges remain: FDA approval is just one step; Medicare coverage and guideline inclusion are key hurdles.Bringing targeted therapy approaches to autoimmune diseases like IBD to improve patient outcomes and reduce costs is Geneoscopy's next goal.Related ContentMultitarget Stool RNA Test for Colorectal Cancer Screening. Barnell EK, Wurtzler EM, La Rocca J, et al. JAMA. 2023;330(18):1760–1768. doi:10.1001/jama.2023.22231Pharmacogenomics (PGx) 101: What You Need to Know for Rx ProgramsReference Materials/Other Links (courtesy of Geneoscopy)Projected Impact and Cost-Effectiveness of Novel Molecular Blood-Based or Stool-Based Screening Tests for Colorectal Cancer. Ladabaum U, Mannalithara A, Schoen RE, Dominitz JA, Lieberman D. Ann Intern Med. 2024 Dec;177(12):1610-1620. doi: 10.7326/ANNALS-24-00910. Epub 2024 Oct 29. PMID: 39467291.Colorectal Cancer—Patient Version. National Cancer Institute (NCI)Productivity savings from colorectal cancer prevention and control strategies. Bradley CJ, Lansdorp-Vogelaar I, Yabroff KR, Dahman B, Mariotto A, Feuer EJ, Brown ML. Am J Prev Med. 2011 Aug;41(2):e5-e14. doi: 10.1016/j.amepre.2011.04.008. PMID: 21767717; PMCID: PMC3139918.Follow Geneoscopy on LinkedInFor more information about Capital Rx and this episode, please visit Capital Rx Insights.

This isn't your father's colonoscopy. Colorectal screening is entering a new era, with innovations that make the process easier, detection earlier and more accessible than ever. From a simple blood test that can detect signs of cancer to AI technology helping doctors catch polyps that might otherwise go unnoticed, today's tools are transforming the screening experience. Whether you're due for your first test or curious about your options, this conversation offers the insight you need to take charge of your colorectal health — with clarity, confidence and peace of mind.Host:Sandra PeeblesAward-Winning JournalistExperts:Victor Maciel, M.D., Colorectal Surgeon at Baptist HealthAriel Sims, M.D., Gastroenterologist at Gastro Health

In this powerful episode, we share a deeply personal story about the devastating impact of early-onset colorectal cancer—and the urgent need for better screening. Our guest, Dr. George Beauregard, is an internal medicine physician and healthcare executive whose world changed forever in 2017 when his newly married 29-year-old son was diagnosed with stage 4 colorectal cancer—just a month after his wedding. Through his son's courageous fight and advocacy, Dr. Beauregard found a renewed purpose: raising awareness about the alarming rise in early-onset cases and the need for improved screening and research. He also shares insights from his memoir, Reservations For Nine: A Doctor's Family Confronts Cancer, blending his personal and professional perspectives. Join us as we discuss his son's lasting legacy, the emotional and medical lessons from their journey, and the fight for earlier detection. This conversation is a call to action for greater awareness, earlier intervention, and meaningful change.  

In this episode of The Real GI Doc Show, Dr. Gandolfo takes a moment to highlight an important guest appearance he made on The Positive Gene Podcast, hosted by cancer previvor and cancer prevention advocate Sara Kavanaugh, in honor of Colorectal Cancer Awareness Month. What is a "previvor" you may ask? A previvor is a survivor of a predisposition for cancer or another disease. In Sara's case that condition is Lynch Syndrome-the most common hereditary cancer predisposition syndrome. With colorectal cancer being the fourth most commonly diagnosed cancer and the second leading cause of cancer death in the United States, Dr. Gandolfo emphasizes the urgency of discussing this critical topic. During the episode, Dr. Gandolfo and Sara delve into various aspects of colorectal cancer, including: - The significance of understanding Lynch Syndrome, a genetic condition that increases the risk of several cancers, including colorectal cancer. - Preventative measures through diet and lifestyle that can help reduce the risk of colorectal cancer. - The concerning rise of colon cancer diagnoses among younger individuals and what symptoms to watch for. - The importance of timely screening and colonoscopy, especially for those with risk factors, regardless of age. Listeners will gain valuable insights into colorectal cancer prevention, the role of genetics in cancer risk, and practical advice for discussing symptoms and screening with healthcare providers. Tune into The Positive Gene Podcast to listen to the full 58-minute interview using the links below: Listen on Apple: https://podcasts.apple.com/us/podcast/the-positive-gene-podcast/id1708990295?i=1000699080929 Listen on Spotify: https://open.spotify.com/episode/53zke5DCLEehnLLLcM2x5P?si=c93068d7a1c549e8 Visit The Positive Gene Podcast page for all other ways to listen: https://thepositivegenepodcast.podbean.com/ Follow Sara Kavanaugh on Instagram https://www.instagram.com/positivegenepodcast/ --- Watch The Real GI Doc Show on YouTube! Click here! Be sure to subscribe to The Real GI Doc Show for more insights, and reach out with your questions on social media @realgidoc or leave an audio question for Dr. Gandolfo here. Find The Real GI Doc Show on social media, join the newsletter, read Dr. Gandolfo's bio, or ask a question using this link.  

In this episode, we highlight a panel of medical experts and community leaders in Ashland County who are sounding the alarm about rising colorectal cancer rates. You’ll hear insights on why local screening rates don’t match the area’s high mortality numbers, a survivor’s powerful call to action, and how environmental factors might be playing a role. Read the full story: https://www.ashlandsource.com/2025/03/19/expert-panel-discusses-colorectal-cancer-rates-in-ashland-county/ Support the show: https://richlandsource.com/membersSee omnystudio.com/listener for privacy information.

Featuring perspectives from Dr Scott Kopetz and Dr Jeffrey Meyerhardt, including the following topics: Introduction (0:00) Cell-Free DNA Molecular Residual Disease Assays in Clinical Practice (3:25) Immunotherapy for Localized and Metastatic Microsatellite Instability-High Colorectal Cancer (28:27) Other Important Datasets (46:06) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 2: Advances in the Management of Metastatic CRC (mCRC) — Scott Kopetz, MD, PhD CME information and select publications

An inside look into how the iconic hit, “We are the World,” came to be. Also, new details on groundbreaking research that's being done to help find cancer before it spreads. And, Regé-Jean Page talks being a secret agent in his new thriller, “Black Bag.” 

Welcome back to today's Friday Review where I'll be breaking down the best of the week!     I'll be sharing specifics on these topics:     Weekly Podcast Recap Coros Pace 3 vs. Apple Watch (product review) Dostarlimab and Endometrial & Colorectal Cancer (research)   For all the details tune in to today's Cabral Concept 3290 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3290 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!